Pterostilbene inhibits gallbladder cancer progression by suppressing the PI3K/Akt pathway

12Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Gallbladder cancer is the most common malignant tumor of the biliary system and is characterized by difficulty to diagnose in early stages, a high degree of malignancy, and poor prognosis. Finding new drugs may improve the prognosis for this dismal cancer. Herein, we investigated the potential application of pterostilbene (PTS) against gallbladder cancer in vivo and in vitro. PTS potently inhibited cell proliferation, migration and invasion of gallbladder cancer cells. Moreover, PTS also had a function of inducing apoptosis in vitro. Meanwhile, PTS reversed EMT with a correlated inhibition of PI3K/Akt activation. Tumor xenograft models showed that PTS inhibited tumor growth and had low toxicity in vivo, which were consistent with the in vitro data. These findings indicate that PTS arrests cell growth through inhibition of PI3K/AKT signaling and is a potential drug for the therapy of gallbladder cancer.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Tong, C., Wang, Y., Li, J., Cen, W., Zhang, W., Zhu, Z., … Lu, B. (2021). Pterostilbene inhibits gallbladder cancer progression by suppressing the PI3K/Akt pathway. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-83924-4

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

67%

Professor / Associate Prof. 2

33%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

33%

Pharmacology, Toxicology and Pharmaceut... 2

33%

Agricultural and Biological Sciences 1

17%

Biochemistry, Genetics and Molecular Bi... 1

17%

Save time finding and organizing research with Mendeley

Sign up for free